Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful ...

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...

A recent study published in Hypertension by Kario et al. (2025) provides compelling evidence that radiofrequency renal ...

As people age, so do their kidneys.1 The average decline in renal function is approximately 1 mL/min/year after 30 years ...

Takeda presents new data showing mezagitamab sustained effect on kidney function 18 months after treatment in primary IgA nephropathy: Osaka, Japan Monday, November 10, 2025, 15:0 ...

Ascendis Pharma recently announced results from a pooled three-year analysis of its Phase 2 and Phase 3 trials showing that adults with hypoparathyroidism treated with TransCon PTH experienced ...

In India, a growing number of young adults are showing higher-than-normal uric acid levels, a condition once seen mostly in ...

A Seemingly Innocent Dietary Choice Turned Into A Dangerous Trigger For Acute Kidney Failure, As Medical Investigators ...

Panelists discuss how payers typically require step therapy with SGLT2 inhibitors before approving nonsteroidal MRAs due to ...

A polypill containing three recommended heart failure therapies improved heart function, reduced hospitalizations and was ...

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of ...

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.